TrialSignal
Clinical trial intelligence report
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Participants With Alzheimer's Disease
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 19, 2026
NCT ID
NCT07599670
Status
RECRUITING
Phase
Phase 1/2
Sponsor
AbbVie
Executive brief
Investment-Ready Snapshot
ABBV-1758 is positioned in the competitive landscape of Alzheimer's disease therapeutics, targeting a significant unmet need in a growing market. With an aging global population, the demand for effective Alzheimer's treatments is escalating. The trial's design, including a diverse participant pool across the U.S., China, and Japan, enhances its potential for broad market applicability. However, the increased treatment burden on participants may impact recruitment and retention. AbbVie’s commitment to responsible clinical trial data sharing may enhance its reputation and facilitate future collaborations.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07599670
Indication
Alzheimer's Disease
Modality
small molecule
Target
Investigational drug ABBV-1758 targets amyloid pathology in Alzheimer's disease.
Intervention
ABBV-1758, Placebo for ABBV-1758, ABBV-1758, Placebo for ABBV-1758
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.